UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Reduces Stock Position in MaxCyte, Inc. (NASDAQ:MXCT)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its stake in MaxCyte, Inc. (NASDAQ:MXCT) by 11.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 203,648 shares of the company’s stock after selling 27,111 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in MaxCyte were worth $792,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the stock. Mudita Advisors LLP boosted its stake in shares of MaxCyte by 5.6% in the 3rd quarter. Mudita Advisors LLP now owns 3,153,441 shares of the company’s stock worth $12,267,000 after buying an additional 167,101 shares during the last quarter. River Global Investors LLP lifted its holdings in MaxCyte by 4.7% in the third quarter. River Global Investors LLP now owns 2,062,562 shares of the company’s stock valued at $8,034,000 after acquiring an additional 93,340 shares during the period. Chevy Chase Trust Holdings LLC boosted its position in MaxCyte by 2.0% in the second quarter. Chevy Chase Trust Holdings LLC now owns 1,322,560 shares of the company’s stock worth $5,184,000 after purchasing an additional 26,163 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in shares of MaxCyte by 13.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,010,292 shares of the company’s stock valued at $3,961,000 after purchasing an additional 121,090 shares during the period. Finally, Marshall Wace LLP bought a new stake in shares of MaxCyte during the 2nd quarter valued at about $1,959,000. 68.81% of the stock is currently owned by hedge funds and other institutional investors.

MaxCyte Stock Down 1.2 %

Shares of NASDAQ:MXCT opened at $4.14 on Friday. The stock has a market capitalization of $437.56 million, a PE ratio of -12.18 and a beta of 1.37. The firm’s 50 day moving average price is $3.74 and its 200-day moving average price is $4.06. MaxCyte, Inc. has a twelve month low of $3.16 and a twelve month high of $5.55.

MaxCyte (NASDAQ:MXCT) last announced its earnings results on Wednesday, November 6th. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.02. The business had revenue of $8.16 million during the quarter, compared to analysts’ expectations of $7.50 million. MaxCyte had a negative net margin of 78.36% and a negative return on equity of 16.00%. During the same period in the prior year, the company earned ($0.11) earnings per share. Analysts expect that MaxCyte, Inc. will post -0.42 earnings per share for the current fiscal year.

Insider Transactions at MaxCyte

In other MaxCyte news, Director Stanley C. Erck sold 21,607 shares of the business’s stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $3.71, for a total transaction of $80,161.97. Following the completion of the sale, the director now owns 269,118 shares of the company’s stock, valued at approximately $998,427.78. The trade was a 7.43 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders sold 27,607 shares of company stock worth $102,782 in the last three months. Corporate insiders own 3.00% of the company’s stock.

MaxCyte Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.